April 25, 2012 11:16 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published earlier today, Canaccord Genuity reiterated its Buy rating for Alexion Pharmaceuticals (NASDAQ: ALXN) and raised its price target from $95.00 to $100.00.Canaccord said in their report “ALXN is seeing Soliris [the trade name for the monoclonal antibody Eculizumab] utilization split somewhat evenly between newly diagnosed patients and those with longer duration of disease (range of ages) treated by hematologists and nephrologists in the critical care and community settings. Uptake is being aided by initiatives focused on disease awareness, diagnosis, reimbursement and Soliris availability (Soliris can be delivered in 6-9 hours to ~85% of patients in the U.S.), particularly in the critical care setting where rapid diagnosis and treatment is essential.”Alexion Pharmaceuticals closed at $88.90 yesterday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.